Education
About Us
Working with TipRanks
Follow Us
FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
FBLG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.98 - $13.59
Previous CloseN/A
Volume56.64K
Average Volume (3M)433.35K
Market Cap
$40.41M
Enterprise Value$97.30M
Total Cash (Recent Filing)$2.27M
Total Debt (Recent Filing)$7.52M
Price to Earnings (P/E)―
Beta0.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding36,408,398
10 Day Avg. Volume222,859
30 Day Avg. Volume433,352
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market Cap2.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-222.66
Enterprise Value/Ebitda-5.65
Forecast
1Y Price Target
$12.00Price Target Upside990.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
FibroBiologics, Inc. News
PremiumCompany Announcements
FibroBiologics Approves Executive Bonuses for 2024PremiumCompany Announcements
FibroBiologics Secures $5M Funding for Strategic GrowthPremiumCompany Announcements
FibroBiologics Secures $25M Equity Agreement for Trials---
Bulls Say, Bears Say
Bulls Say
Market OpportunityChronic wound care represents a sizable market with $28B in healthcare spending, providing a significant opportunity for FibroBiologics.
Therapeutic BenefitFibroblast therapies offer a differentiated therapeutic benefit, addressing unmet needs in connective tissue formation and wound healing.
Bears Say
Financial PerformanceFibrobiologics reported 3Q24 results with an operating loss of ($3.4M) and cash of $7.8M.
---
Ownership Overview
16.25%
Insiders
3.99%
Mutual Funds
2.16% Other Institutional Investors
72.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.98 and its highest was $13.59 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $40.41M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on May 14, 2024. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.27.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 36,408,398 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.839%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Among the largest hedge funds holding FibroBiologics, Inc.’s share is Fund Evaluation Group, LLC. It holds FibroBiologics, Inc.’s shares valued at 0.
---
FibroBiologics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (990.91% Upside)
$12.00 (990.91% Upside)
Blogger Sentiment
Bullish
FBLG Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.56%
12-Months-Change
Fundamentals
Return on Equity
-267.86%
Trailing 12-Months
Asset Growth
-21.28%
Trailing 12-Months
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc.
---
FBLG Stock 12 Month Forecast
Average Price Target
$12.00
▲(990.91% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
FibroGen
―
Blueprint Medicines
―
Arcus Biosciences
―
Best Analysts Covering FBLG
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-46.70%
reiterated a buy rating 28 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -46.70% per trade.
---